Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 676 to 690 of 1455 results for do not do recommendations

  1. Dual‑chamber pacemakers for symptomatic bradycardia due to sick sinus syndrome without atrioventricular block (TA324)

    Evidence-based recommendations on dual-chamber pacemakers for treating symptomatic bradycardia caused by sick sinus syndrome without atrioventricular block.

  2. General practice

    to bring a primary care perspective to the guidance that we produce. They do this by taking part in the committees that develop our...

  3. Empagliflozin in combination therapy for treating type 2 diabetes (TA336)

    Evidence-based recommendations on empagliflozin (Jardiance) in combination therapy for treating type 2 diabetes.

  4. Axicabtagene ciloleucel for treating relapsed or refractory follicular lymphoma (TA894)

    Evidence-based recommendations on axicabtagene ciloleucel (Yescarta) for relapsed or refractory follicular lymphoma in adults.

  5. Guide to the processes of technology appraisal (PMG19)

    Guide to the processes of technology appraisal

  6. Apremilast for treating moderate to severe plaque psoriasis (TA419)

    Evidence-based recommendations on apremilast (Otezla) for treating moderate to severe plaque psoriasis in adults.

  7. Denosumab for the prevention of osteoporotic fractures in postmenopausal women (TA204)

    Evidence-based recommendations on denosumab (Prolia) for preventing osteoporotic fragility fractures in postmenopausal women.

  8. Serious eye disorders (QS180)

    This quality standard covers the diagnosis and management of cataracts, glaucoma and age-related macular degeneration (AMD) and the prevention of sight loss. It describes high-quality care in priority areas for improvement.

  9. NICE health technology evaluation topic selection: the manual (PMG37)

    This is not the current manual. From 29 May 2024, health technologies are selected using the new NICE-wide topic prioritisation process (PMG46)

  10. Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure (TA626)

    Evidence-based recommendations on avatrombopag (Doptelet) for treating severe thrombocytopenia in adults with chronic liver disease needing a planned invasive procedure.

  11. SEM Scanner 200 for preventing pressure ulcers (MTG51)

    Evidence-based recommendations on SEM Scanner 200 for preventing pressure ulcers.

  12. Interim process and methods guide for the clinical guideline updates using standing committees pilot programme 2013 (PMG17)

    Interim process and methods guide for the clinical guideline updates using standing committees pilot programme 2013

  13. Abiraterone for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer (TA721)

    Evidence-based recommendations on abiraterone (Zytiga) for newly diagnosed high-risk hormone-sensitive metastatic prostate cancer in adults.

  14. Beta interferons and glatiramer acetate for treating multiple sclerosis (TA527)

    Evidence-based recommendations on beta interferons (Avonex, Betaferon, Extavia, Rebif) and glatiramer acetate (Copaxone) for treating multiple sclerosis in adults.